Articles by Nick Paul Taylor
The growing need for computer-enabled capabilities in drug development has led to the creation of biotech-focused software startups. And the obvious base for these startups is the one part of the U.S. where biotech and tech hubs are co-located: San Francisco.
This week FDA officially introduced its push to open up its data to the public and particularly app developers. The unveiling went over the goals of openFDA, but also detailed some other areas in which the agency is investing. FDA is pushing hard into NGS and cloud-based genomics.
The Global Alliance for Genomics and Health was thrust into the headlines last week when Google joined its ranks. This week it met for the first time to discuss its goals. Development of an open-source public application programming interface (API) for sequencing reads and genetic variants is high on the agenda.
The use of genomics to understand aging has become a high-profile field in recent months, with J. Craig Venter's Human Longevity and Google's Calico both researching the topic. Now Scripps has given the rest of the sector a new resource--whole genome sequences of 454 healthy elderly people.
The account--elilillyco--has posted old photographs of Lilly's facilities and researchers alongside pictures of what its current staff are doing.
Over the past decade a plethora of digital formats have begun competing with print, television, radio and conferences for biopharma marketeers' budgets. And while initial uptake was slow, a survey has now found Big Data, social media and mobile have doubled their share of the marketing mix since 2012.
The company J. Craig Venter founded in 1998 to challenge the Human Genome Project ran a data center with 70 terabytes of storage. Venter's latest scheme--creating the world's largest sequencing center--will fill that in less than one week.
U.K. begins trying to rebuild trust in patient database after months of 'confusion, suspicion and anxiety'
The United Kingdom's long history of public healthcare gives it an enviable trove of patient data. Yet this resource, which is perhaps the one true competitive edge possessed by U.K. biopharma, is at risk of being squandered as the project continues to buried by mismanagement and a blizzard of negative publicity.
During a week in which The Guardian revealed that Britain intercepted and stored webcam images from millions of people, the FDA email snooping revealed in 2012 looks relatively innocent. But Republicans investigating the program think the regulator may have violated whistleblower laws by monitoring employees' emails.
The information comes from Genetic Epidemiology Research on Aging (GERA), a cohort of more than 100,000 adults with an average age of 63 years old.